***PKTX..ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease
Marietta, Ohio, March 19, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP® molecule.
During recent testing conducted by EyeCRO of Oklahoma City, using a well-established animal model for Dry Eye Disease (DED), and Ocular Inflammation it was observed that AAGP® may have a substantial effect on the suppression and control of the disease. Based on these results the company has filed for patent protection with the United States Patent and Trademark Office (USPTO) for the application of DED. The patent application was submitted for both human and veterinary uses.
Dry Eye Disease is one of the most common ocular problems with an estimated prevalence of almost 5-million people over the age of fifty in the United States alone. Current therapies for dry eye are palliative with a focus on the replacement of tears to reduce symptoms. Over-the-counter artificial tear formulations are available. Punctual palliative therapies are also available, and while they have benefits over the short term, they have limited utility in long-term control therapy for dry eye. Cyclosporine A is the first prescription product for dry eye therapy, which increases tear production in patients whose tear production is suppressed. However, Cyclosporine A treatment presents disadvantages over the long term which could potentially be mitigated by AAGP®.
By protecting this technology, the Company is in a better position to move forward with its research in ophthalmological therapies.
“Following the successful completion of recent testing of our AAGP® for dry eye disease, we need to ensure all our intellectual property is patented in order to protect its value.” - said Clarence E. Smith, president and chief executive officer.